113 related articles for article (PubMed ID: 1277210)
1. Cyclic phosphoramide mustard (NSC-69945) derivatives of amino acids and peptides.
Szekerke M
Cancer Treat Rep; 1976 Apr; 60(4):347-54. PubMed ID: 1277210
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationships of pre-activated analogs of cyclophosphamide (NSC-26271).
Montgomery JA; Struck RF
Cancer Treat Rep; 1976 Apr; 60(4):381-93. PubMed ID: 945126
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
Friedman OM; Wodinsky I; Myles A
Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.
Brock N
Cancer Treat Rep; 1976 Apr; 60(4):301-8. PubMed ID: 1277205
[TBL] [Abstract][Full Text] [Related]
5. Alkylating properties of phosphoramide mustard.
Colvin M; Brundrett RB; Kan MN; Jardine I; Fenselau C
Cancer Res; 1976 Mar; 36(3):1121-6. PubMed ID: 1253171
[TBL] [Abstract][Full Text] [Related]
6. Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes.
Cox PJ; Phillips BJ; Thomas P
Cancer Treat Rep; 1976 Apr; 60(4):321-6. PubMed ID: 179712
[TBL] [Abstract][Full Text] [Related]
7. Potential anticancer agents. XVII. New developments in the benzoic acid nitrogen mustards area.
Niculescu-Duvăz I; Feyns V; Dobre V
Cancer Treat Rep; 1978 Dec; 62(12):2045-54. PubMed ID: 751714
[TBL] [Abstract][Full Text] [Related]
8. [Potential anticancer agents. 3. Preparation of amino acid derivatives of bis(beta-chloroethyl)-phosphoramidic dichloride].
Sung WL; Hou SZ; Zhao HP; Yang JH; Ja XX
Yao Xue Xue Bao; 1966 Feb; 13(2):126-30. PubMed ID: 5952403
[No Abstract] [Full Text] [Related]
9. Characterization of cyclophosphamide (NSC-26271) metabolites and related derivatives by field-desorption and electron-impact mass spectrometry.
Przybylski M; Ringsdorf H; Voelcker G; Draeger U; Peter G; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):509-16. PubMed ID: 1277228
[TBL] [Abstract][Full Text] [Related]
10. Stereochemistry, metabolism, and antitumor activity of 4-hydroperoxyisophosphamide (NSC-227114) and its stereoisomer.
Takamizawa A; Iwata T; Yamaguchi K; Shiratori O; Harada M
Cancer Treat Rep; 1976 Apr; 60(4):361-8. PubMed ID: 1277212
[TBL] [Abstract][Full Text] [Related]
11. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
Hemminki K
Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
[TBL] [Abstract][Full Text] [Related]
12. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
13. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.
Peter G; Wagner T; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):429-35. PubMed ID: 1277218
[TBL] [Abstract][Full Text] [Related]
14. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice.
Cantrell JE; Green D; Schein PS
Cancer Res; 1986 May; 46(5):2340-3. PubMed ID: 2938728
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
Chang TK; Waxman DJ
Cancer Res; 1993 Jun; 53(11):2490-7. PubMed ID: 8495410
[TBL] [Abstract][Full Text] [Related]
17. Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites.
Jardine I; Brundrett R; Colvin M; Fenselau C
Cancer Treat Rep; 1976 Apr; 60(4):403-8. PubMed ID: 1277214
[TBL] [Abstract][Full Text] [Related]
18. Research on compounds with antiblastic activity. XXX. p-(N,N-bis-(beta-chloroethyl)amino)benzylidene derivatives of some cyclopentanones.
Giuliano R; Ermili A; Artico M; Grundmann E; Bierling R; Steinhoff D
Farmaco Sci; 1967 Apr; 22(4):258-71. PubMed ID: 5608225
[No Abstract] [Full Text] [Related]
19. Antitumor effect of N alpha-benzyloxycarbonyl-N,N-bis-(2-halogenethyl)-hydrazide derivatives of amino acids.
Karaivanova MH; Zakhariev SG; Golovinsky EV
Neoplasma; 1980; 27(2):137-42. PubMed ID: 7393353
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity and DNA cross-linking activity of 4-sulfidocyclophosphamides in mouse leukemia cells in vitro.
Erickson LC; Ramonas LM; Zaharko DS; Kohn KW
Cancer Res; 1980 Nov; 40(11):4216-20. PubMed ID: 7471062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
